Tradestie Institutional Equity Comparison Engine

CRBP vs ANRO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ANRO Overall Edge

ANRO Captures Institutional Edge (3โ€“0 Pillars ยท 5โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Alto Neuroscience Inc. (ANRO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CRBP trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus ANRO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CRBP sits in BREAKDOWN (66th %ile IV; Dealer Gamma Walls on Pro) against ANRO sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
CRBP N/M vs ANRO N/M Fwd P/E
Growth & Margin Winner ANRO
Op Margin 0.0% vs 0.0% ยท YoY -100.0% vs +0.0%
Momentum & Technical Winner ANRO
1Y -69.5% vs +138.9% ยท 52W Pos 6% vs 61%
Options & Structure Winner ANRO
BREAKDOWN (66th %ile IV) vs BREAKDOWN (8th %ile IV)
CRBP NASDAQ
Corbus Pharmaceuticals Holdings, Inc.
Pharmaceutical Preparations
$3.38
-0.44% 1D
Market Cap $69.9M
1M Return -25.33%
1Y Return -69.51%
Forward P/E N/M
Unified AI Score
45.0 / 100 HOLD
Tech 43.0 Fund 54.0 Flow 69.0 Mom 64.0
ANRO NYSE
Alto Neuroscience Inc.
Pharmaceutical Preparations
$27.12
-8.19% 1D
Market Cap $1.2B
1M Return +23.61%
1Y Return +138.94%
Forward P/E N/M
Unified AI Score
29.2 / 100 SELL
Tech 50.0 Fund 33.0 Flow 65.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CRBP -69.51% ANRO +138.94% Spread: +208.45 pp (ANRO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CRBP TTM Op. Margin: 0.0% ANRO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRBP vs ANRO. Trailing 12-month operating profitability (CRBP 0.0% vs ANRO 0.0%) and valuation multiples (CRBP N/M vs ANRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CRBP (1) vs ANRO (5)
Institutional Metric CRBP ANRO Criterion Row Winner
Market Capitalization Scale $69.9M $1.2B Larger Scale ANRO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -100.0% +0.0% Higher Growth ANRO
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -131.5% -46.7% Higher ROE ANRO
52-Week Range Position Momentum 6% ($3โ€“$13) 61% ($11โ€“$37) Stronger Trend ANRO
Beta / 30D Volatility Risk Regime 1.93ฮฒ ยท 121% Vol 1.95ฮฒ ยท 90% Vol Lower Realized Risk ANRO
Unified Institutional Score Composite Signal 45.0 / 100 (HOLD) 29.2 / 100 (SELL) Higher Composite CRBP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CRBP vs ANRO Buy Guide
CRBP BREAKDOWN
58d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 66th %ile
IV Regime Elevated (60thโ€“80th %ile)
Live CRBP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ANRO BREAKDOWN
57d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live ANRO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CRBP nor ANRO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.